The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients: Is there a room for vitamin D?

Hatouf H. Sukkarieh; Rami T. Bustami; Manasik N. Abdu; Ayesha A. Khokhar; Amir A. Salih; Hana K. Abdalla

doi:10.15537/smj.2020.10.25428

References

↵
1. Tesch GH
(2017) Diabetic nephropathy - is this an immune disorder? Clinical Science 131:2183–2199.
OpenUrl Abstract/FREE Full Text
↵
1. Donnelly R
(2000) ABC of arterial and venous disease:Vascular complications of diabetes. BMJ 320:1062–1066.
OpenUrl FREE Full Text
↵
1. Vivian EM,
2. Rubinstein GB
(2002) Pharmacologic management of diabetic nephropathy. Clinical Therapeutics 24:1741–1756.
OpenUrl CrossRef PubMed Web of Science
↵
1. Amann B,
2. Tinzmann R,
3. Angelkort B
(2003) ACE Inhibitors Improve Diabetic Nephropathy Through Suppression of Renal MCP-1. Diabetes Care 26:2421–2425.
OpenUrl Abstract/FREE Full Text
↵
1. Park C,
2. Wang G,
3. Ng BP,
4. Fang J,
5. Durthaler JM,
6. Ayala C
(2020) The uses and expenses of antihypertensive medications among hypertensive adults. Research in Social and Administrative Pharmacy 16:183–189.
OpenUrl
↵
1. Hsu FY,
2. Lin FJ,
3. Ou HT,
4. Huang SH,
5. Wang CC
(2017) Renoprotective Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic patients with proteinuria. Kidney Blood Press Res 42:358–368.
OpenUrl CrossRef PubMed
1. Herman WH
(2015) Response to Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. InStandards of Medical Care in Diabetes-2015. Diabetes Care 38(Suppl. 1):S41–S48.
OpenUrl FREE Full Text
1. Fried LF,
2. Emanuele N,
3. Zhang JH,
4. Brophy M,
5. Conner TA,
6. Duckworth W,
7. et al.
(2013) Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy. New England Journal of Medicine 369:1892–1903.
OpenUrl CrossRef PubMed Web of Science
↵
1. Juarez GF,
2. Luño J,
3. Barrio V,
4. Vinuesa SGD,
5. Praga M,
6. Goicoechea M,
7. et al.
(2013) Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy:A randomized trial. Am J Kidney Dis 61:211–218.
OpenUrl CrossRef PubMed
↵
1. Ponikowski P,
2. Voors AA,
3. Anker SD,
4. Bueno H,
5. Cleland JG,
6. Coats AJ,
7. et al.
(2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal 37:2129–2200.
OpenUrl CrossRef PubMed
↵
1. Schmidt M,
2. Mansfield KE,
3. Bhaskaran K,
4. Nitsch D,
5. Sørensen HT,
6. Smeeth L,
7. Tomlinson LA
(2017) Adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin-angiotensin system blockade:a UK general practice-based cohort study. BMJ Open 7:e012818.
OpenUrl Abstract/FREE Full Text
↵
1. Aljack H,
2. Abdalla M,
3. Idris O,
4. Ismail A
(2019) Vitamin D deficiency increases risk of nephropathy and cardiovascular diseases in Type 2 diabetes mellitus patients. Journal of Research in Medical Sciences 24:47.
OpenUrl
↵
1. Usluogullari CA,
2. Balkan F,
3. Caner S,
4. Ucler R,
5. Kaya C,
6. Ersoy R,
7. et al.
(2015) The relationship between microvascular complications and vitamin D deficiency in type 2 diabetes mellitus. BMC Endocrine Disorders 15(1).
↵
1. Senyigit A
(2019) The association between 25-hydroxy vitamin D deficiency and diabetic complications in patients with type 2 diabetes mellitus. Diabetes &Metabolic Syndrome:Clinical Research &Reviews 13:1381–1386.
OpenUrl
↵
1. Tiryaki Ö,
2. Usalan C,
3. Sayiner ZA
(2015) Vitamin D receptor activation with calcitriol for reducing urinary angiotensinogen in patients with type 2 diabetic chronic kidney disease. Renal Failure 38:222–227.
OpenUrl
↵
1. Peng Y,
2. Li LJ
(2015) Serum 25-hydroxyvitamin D level and diabetic nephropathy in patients with type 2 diabetes mellitus. International Urology and Nephrology 47:983–989.
OpenUrl
↵
1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease:evaluation, classification and stratification
(2002) Am J Kidney Dis 39(Suppl 1):S46–S64.
OpenUrl CrossRef
↵
1. American Diabetes Association. Executive Summary:Standards of Medical Care in Diabetes-2011
(2011) Diabetes Care 34(Supplement 1):S4–S10.
OpenUrl FREE Full Text
↵
1. Bakris GL,
2. Weir MR
(2000) Angiotensin-Converting Enzyme Inhibitor-Associated Elevations in Serum Creatinine. Archives of Internal Medicine 160:5.
OpenUrl
↵
1. Lv J,
2. Perkovic V,
3. Foote CV,
4. Craig ME,
5. Craig JC,
6. Strippoli GF
(2012) Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 12:CD004136.
OpenUrl PubMed
↵
1. Mann JF,
2. Schmieder RE,
3. Mcqueen M,
4. Dyal L,
5. Schumacher H,
6. Pogue J,
7. et al.
(2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study):a multicentre, randomised, double-blind, controlled trial. The Lancet 372:547–553.
OpenUrl
↵
1. Chokhandre MK,
2. Mahmoud MI,
3. Hakami T,
4. Jafer M,
5. Inamdar AS
(2015) Vitamin D &its analogues in type 2 diabetic nephropathy:a systematic review. Journal of Diabetes &Metabolic Disorders 14:58.
OpenUrl
↵
1. Al-Alyani H,
2. Al-Turki HA,
3. Al-Essa ON,
4. Alani FM,
5. Sadat-Ali M
(2018) Vitamin D deficiency in Saudi Arabians:a reality or simply hype:a meta-analysis (2008-2015). Journal of Family &Community Medicine 25:1.
OpenUrl
↵
1. Al-Rubeaan K,
2. Siddiqui K,
3. Al-Ghonaim MA,
4. Youssef AM,
5. AlNaqeeb D
(2018) The Saudi Diabetic Kidney Disease study (Saudi-DKD):clinical characteristics and biochemical parameters. Ann Saudi Med 38:46–56.
OpenUrl

In this issue

Download PDF

Email Article

Citation Tools

Bookmark this article

Cited By...

Google Scholar

More in this TOC Section

Show more Original Article

Keywords

[1] ↵
Tesch GH
(2017) Diabetic nephropathy - is this an immune disorder? Clinical Science 131:2183–2199.
OpenUrl Abstract/FREE Full Text

[2] Tesch GH

[3] ↵
Donnelly R
(2000) ABC of arterial and venous disease:Vascular complications of diabetes. BMJ 320:1062–1066.
OpenUrl FREE Full Text

[4] Donnelly R

[5] ↵
Vivian EM,
Rubinstein GB
(2002) Pharmacologic management of diabetic nephropathy. Clinical Therapeutics 24:1741–1756.
OpenUrl CrossRef PubMed Web of Science

[6] Vivian EM,

[7] Rubinstein GB

[8] ↵
Amann B,
Tinzmann R,
Angelkort B
(2003) ACE Inhibitors Improve Diabetic Nephropathy Through Suppression of Renal MCP-1. Diabetes Care 26:2421–2425.
OpenUrl Abstract/FREE Full Text

[9] Amann B,

[10] Tinzmann R,

[11] Angelkort B

[12] ↵
Park C,
Wang G,
Ng BP,
Fang J,
Durthaler JM,
Ayala C
(2020) The uses and expenses of antihypertensive medications among hypertensive adults. Research in Social and Administrative Pharmacy 16:183–189.
OpenUrl

[13] Park C,

[14] Wang G,

[15] Ng BP,

[16] Fang J,

[17] Durthaler JM,

[18] Ayala C

[19] ↵
Hsu FY,
Lin FJ,
Ou HT,
Huang SH,
Wang CC
(2017) Renoprotective Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic patients with proteinuria. Kidney Blood Press Res 42:358–368.
OpenUrl CrossRef PubMed

[20] Hsu FY,

[21] Lin FJ,

[22] Ou HT,

[23] Huang SH,

[24] Wang CC

[25] Herman WH
(2015) Response to Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. InStandards of Medical Care in Diabetes-2015. Diabetes Care 38(Suppl. 1):S41–S48.
OpenUrl FREE Full Text

[26] Herman WH

[27] Fried LF,
Emanuele N,
Zhang JH,
Brophy M,
Conner TA,
Duckworth W,
et al.
(2013) Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy. New England Journal of Medicine 369:1892–1903.
OpenUrl CrossRef PubMed Web of Science

[28] Fried LF,

[29] Emanuele N,

[30] Zhang JH,

[31] Brophy M,

[32] Conner TA,

[33] Duckworth W,

[34] et al.

[35] ↵
Juarez GF,
Luño J,
Barrio V,
Vinuesa SGD,
Praga M,
Goicoechea M,
et al.
(2013) Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy:A randomized trial. Am J Kidney Dis 61:211–218.
OpenUrl CrossRef PubMed

[36] Juarez GF,

[37] Luño J,

[38] Barrio V,

[39] Vinuesa SGD,

[40] Praga M,

[41] Goicoechea M,

[42] et al.

[43] ↵
Ponikowski P,
Voors AA,
Anker SD,
Bueno H,
Cleland JG,
Coats AJ,
et al.
(2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal 37:2129–2200.
OpenUrl CrossRef PubMed

[44] Ponikowski P,

[45] Voors AA,

[46] Anker SD,

[47] Bueno H,

[48] Cleland JG,

[49] Coats AJ,

[50] et al.

[51] ↵
Schmidt M,
Mansfield KE,
Bhaskaran K,
Nitsch D,
Sørensen HT,
Smeeth L,
Tomlinson LA
(2017) Adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin-angiotensin system blockade:a UK general practice-based cohort study. BMJ Open 7:e012818.
OpenUrl Abstract/FREE Full Text

[52] Schmidt M,

[53] Mansfield KE,

[54] Bhaskaran K,

[55] Nitsch D,

[56] Sørensen HT,

[57] Smeeth L,

[58] Tomlinson LA

[59] ↵
Aljack H,
Abdalla M,
Idris O,
Ismail A
(2019) Vitamin D deficiency increases risk of nephropathy and cardiovascular diseases in Type 2 diabetes mellitus patients. Journal of Research in Medical Sciences 24:47.
OpenUrl

[60] Aljack H,

[61] Abdalla M,

[62] Idris O,

[63] Ismail A

[64] ↵
Usluogullari CA,
Balkan F,
Caner S,
Ucler R,
Kaya C,
Ersoy R,
et al.
(2015) The relationship between microvascular complications and vitamin D deficiency in type 2 diabetes mellitus. BMC Endocrine Disorders 15(1).

[65] Usluogullari CA,

[66] Balkan F,

[67] Caner S,

[68] Ucler R,

[69] Kaya C,

[70] Ersoy R,

[71] et al.

[72] ↵
Senyigit A
(2019) The association between 25-hydroxy vitamin D deficiency and diabetic complications in patients with type 2 diabetes mellitus. Diabetes &Metabolic Syndrome:Clinical Research &Reviews 13:1381–1386.
OpenUrl

[73] Senyigit A

[74] ↵
Tiryaki Ö,
Usalan C,
Sayiner ZA
(2015) Vitamin D receptor activation with calcitriol for reducing urinary angiotensinogen in patients with type 2 diabetic chronic kidney disease. Renal Failure 38:222–227.
OpenUrl

[75] Tiryaki Ö,

[76] Usalan C,

[77] Sayiner ZA

[78] ↵
Peng Y,
Li LJ
(2015) Serum 25-hydroxyvitamin D level and diabetic nephropathy in patients with type 2 diabetes mellitus. International Urology and Nephrology 47:983–989.
OpenUrl

[79] Peng Y,

[80] Li LJ

[81] ↵
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease:evaluation, classification and stratification
(2002) Am J Kidney Dis 39(Suppl 1):S46–S64.
OpenUrl CrossRef

[82] National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease:evaluation, classification and stratification

[83] ↵
American Diabetes Association. Executive Summary:Standards of Medical Care in Diabetes-2011
(2011) Diabetes Care 34(Supplement 1):S4–S10.
OpenUrl FREE Full Text

[84] American Diabetes Association. Executive Summary:Standards of Medical Care in Diabetes-2011

[85] ↵
Bakris GL,
Weir MR
(2000) Angiotensin-Converting Enzyme Inhibitor-Associated Elevations in Serum Creatinine. Archives of Internal Medicine 160:5.
OpenUrl

[86] Bakris GL,

[87] Weir MR

[88] ↵
Lv J,
Perkovic V,
Foote CV,
Craig ME,
Craig JC,
Strippoli GF
(2012) Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 12:CD004136.
OpenUrl PubMed

[89] Lv J,

[90] Perkovic V,

[91] Foote CV,

[92] Craig ME,

[93] Craig JC,

[94] Strippoli GF

[95] ↵
Mann JF,
Schmieder RE,
Mcqueen M,
Dyal L,
Schumacher H,
Pogue J,
et al.
(2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study):a multicentre, randomised, double-blind, controlled trial. The Lancet 372:547–553.
OpenUrl

[96] Mann JF,

[97] Schmieder RE,

[98] Mcqueen M,

[99] Dyal L,

[100] Schumacher H,

[101] Pogue J,

[102] et al.

[103] ↵
Chokhandre MK,
Mahmoud MI,
Hakami T,
Jafer M,
Inamdar AS
(2015) Vitamin D &its analogues in type 2 diabetic nephropathy:a systematic review. Journal of Diabetes &Metabolic Disorders 14:58.
OpenUrl

[104] Chokhandre MK,

[105] Mahmoud MI,

[106] Hakami T,

[107] Jafer M,

[108] Inamdar AS

[109] ↵
Al-Alyani H,
Al-Turki HA,
Al-Essa ON,
Alani FM,
Sadat-Ali M
(2018) Vitamin D deficiency in Saudi Arabians:a reality or simply hype:a meta-analysis (2008-2015). Journal of Family &Community Medicine 25:1.
OpenUrl

[110] Al-Alyani H,

[111] Al-Turki HA,

[112] Al-Essa ON,

[113] Alani FM,

[114] Sadat-Ali M

[115] ↵
Al-Rubeaan K,
Siddiqui K,
Al-Ghonaim MA,
Youssef AM,
AlNaqeeb D
(2018) The Saudi Diabetic Kidney Disease study (Saudi-DKD):clinical characteristics and biochemical parameters. Ann Saudi Med 38:46–56.
OpenUrl

[116] Al-Rubeaan K,

[117] Siddiqui K,

[118] Al-Ghonaim MA,

[119] Youssef AM,

[120] AlNaqeeb D

Main menu

User menu

Search

The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients

Is there a room for vitamin D?

References

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords

CONTENT

JOURNAL

AUTHORS

Main menu

User menu

Search

The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients

Is there a room for vitamin D?

References

In this issue

Citation Manager Formats

Jump to section

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords

CONTENT

JOURNAL

AUTHORS